Literature DB >> 17003927

Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran.

Ali Taher1, Hussain Isma'eel, Ghassan Mehio, Daniela Bignamini, Antonis Kattamis, Eliezer A Rachmilewitz, Maria Domenica Cappellini.   

Abstract

Beta-thalassaemia is a congenital haemolytic anaemia characterized by partial (intermedia, TI) or complete (major, TM) deficiency in the production of beta-globin chains. The primary aim of this study was to determine the prevalence of thromboembolic events in patients with beta-thalassaemia. To achieve this, a multiple choice questionnaire was sent to 56 tertiary referral centres in eight countries (Lebanon, Italy, Israel, Greece, Egypt, Jordan, Saudi Arabia and Iran), requesting specific information on patients who had experienced a thromboembolic event. The study demonstrated that thromboembolic events occurred in a clinically relevant proportion (1.65%) of 8,860 thalassaemia patients (TI - 24.7% or TM - 75.3%) from the Mediterranean and Iran. Thromboembolism occurred 4.38 times more frequently in TI than TM (p < 0.001), with more venous events occurring in TI and more arterial events occurring in TM. Thrombosis in thalassaemia was also more common in females, splenectomized patients and those with profound anaemia (haemoglobin <9 g/dl). Due to the increased risk of thromboembolic events, the rationale for splenectomy should perhaps be re-assessed and the role of transfusion therapy for the prophylaxis of thrombosis, among other complications, be evaluated prospectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003927

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  68 in total

Review 1.  Hypercoagulability in congenital haemolytic anaemias.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2012-10-25       Impact factor: 3.443

Review 2.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

4.  Extramedullary haematopoiesis correlates with genotype and absence of cardiac iron overload in polytransfused adults with thalassaemia.

Authors:  Paolo Ricchi; Massimiliano Ammirabile; Anna Spasiano; Silvia Costantini; Tiziana Di Matola; Alessia Pepe; Patrizia Cinque; Leonilde Pagano; Maddalena Casale; Aldo Filosa; Luciano Prossomariti
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

5.  Thalassemic erythrocytes release microparticles loaded with hemichromes by redox activation of p72Syk kinase.

Authors:  Emanuela Ferru; Antonella Pantaleo; Franco Carta; Franca Mannu; Amina Khadjavi; Valentina Gallo; Luisa Ronzoni; Giovanna Graziadei; Maria Domenica Cappellini; Francesco Turrini
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

Review 6.  Hypercoagulability and thrombotic complications in hemolytic anemias.

Authors:  Kenneth I Ataga
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

7.  A thalassaemia intermedia case with concomitant left atrial thrombus.

Authors:  Cem Sahin; Ozcan Basaran; Yasar Topal; Fatih Akin
Journal:  BMJ Case Rep       Date:  2014-06-20

8.  The life of patients with thalassemia major.

Authors:  Caterina Borgna-Pignatti
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

9.  Prevalence of thrombotic risk factors among beta-thalassemia patients from Western Iran.

Authors:  Zohreh Rahimi; Mandana Ghaderi; Ronald L Nagel; Adriana Muniz
Journal:  J Thromb Thrombolysis       Date:  2007-11-04       Impact factor: 2.300

10.  Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication.

Authors:  Rakhi P Naik; Michael B Streiff; Carlton Haywood; Julie A Nelson; Sophie Lanzkron
Journal:  Am J Med       Date:  2013-05       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.